Stockreport

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia [Yahoo! Finance]

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF Mezagitamab Had a Favorable Safety Profile, with No New Safety Signals Takeda Plans to Initiate Global Phase 3 Trial of Mezagitamab in ITP in the Second Half of FY202 [Read more]